The following is a summary of some recent studies on COVID-19. This includes research results that warrant further studies to confirm the results and that have yet to be certified through peer review.
Most unvaccinated children lack antibodies after COVID-19
Most children and adolescents do not have COVID-19 antibodies in their blood after recovering from SARS-CoV-2 infection, new data confirm.
As of October 2020, researchers in Texas recruited 218 subjects between the ages of 5 and 19 who had recovered from COVID infections at some point in the past. Each provided three blood samples at three month intervals. More than 90% were not vaccinated at study entry. The first blood test showed infection-related antibodies in only a third of the children, the researchers reported online on Friday in Pediatrics. Six months later, only half of those with the antibodies still had them. The study was designed to detect the presence of antibodies, which are just a component of the immune system’s defences, not the amount of antibodies. The level of protection even in those with antibodies is unclear. The researchers found no differences based on whether a child was asymptomatic, the severity of symptoms, when they had the virus, or based on weight or gender.
“It was the same for everyone,” Sarah Messiah of the UTHealth School of Public Health Dallas said in a statement. “Some parents … think just because their child had COVID-19 they are now protected and don’t need to get vaccinated,” Messiah said. “We have a great tool at our disposal to give children extra protection by getting their vaccination.”
The experimental GSK vaccine shows promise against Omicron
A booster shot of an experimental vaccine being developed by GSK (GSK.L) has shown ‘durable protection’ against the omicron variant in rhesus monkeys, new data show.
The monkeys had received two initial doses of vaccine plus a booster dose 6 or 12 months later. Blood samples from the boosted primates showed “remarkably high” levels of antibodies that could neutralize both the original strain of the virus and the omicron variant that led to a spike in infections, the researchers reported Sunday on bioRxiv ahead of the peer review. The immune defenses of the second-line animals are also “substantial and persistent,” they said. The vaccine, dubbed GBP510 and developed in collaboration with SK Bioscience (302440.KS), triggers immune system responses by releasing copies of a key part of the spike protein from the surface of the coronavirus. The protein “subunits” are attached to nanoparticles to resemble the virus itself. These components are supplemented with an adjuvant that boosts immune system responses, explained Bali Pulendran of Stanford University in California.
“The two-dose vaccination…followed by a booster dose a year later…plus adjuvant resulted in highly durable antibody responses and protection from Omicron infection, even six months later,” Pulendran said. Large late-stage studies of GBP510 in humans are ongoing.
AstraZeneca drug less protective over Omicron in transplant patients
AstraZeneca’s (AZN.L) antibody shots, which are given to prevent COVID-19 in high-risk children and adults with compromised immune systems, do not adequately protect organ transplant recipients from the Omicron variant, researchers found.
The drug Evusheld protected against the Delta variant in kidney transplant recipients, and laboratory test results released Monday show Evusheld can neutralize Omicron in mice, including the highly contagious BA.2 version. But among 416 kidney recipients treated with Evusheld after Omicron became the predominant variant, 9.4% developed symptomatic breakthrough infections, with one in three of those patients requiring hospitalization, researchers reported Saturday on medRxiv ahead of the peer review. Two patients died from COVID-19. In laboratory experiments, the researchers exposed the BA.1 version of Omicron, which caused the massive winter flood, to blood samples from 15 Evusheld-treated patients. None of the samples could neutralize the virus.
The US Food and Drug Administration recently advised that higher doses of Evusheld are likely required to prevent Omicron infection and that patients who received the originally approved vaccines should receive booster doses. The researchers said kidney transplant recipients “should be advised to maintain sanitary protections and undergo immunizations.”
Most unvaccinated children lack antibodies after COVID; GSK Vaccine Shows Promise Compared to Omicron – SABC News
Source link Most unvaccinated children lack antibodies after COVID; GSK Vaccine Shows Promise Compared to Omicron – SABC News